Informationen:
Fehler:
ID
16190
Beschreibung
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT00171340
Link
https://clinicaltrials.gov/show/NCT00171340
Stichworte
Versionen (1)
- 04.07.16 04.07.16 -
Hochgeladen am
4. Juli 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Bone Loss NCT00171340
Eligibility Bone Loss NCT00171340
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Bone Loss NCT00171340
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Breast Carcinoma | TNM clinical staging
Item
stage i-iiia breast cancer
boolean
C0678222 (UMLS CUI [1])
C3258246 (UMLS CUI [2])
C3258246 (UMLS CUI [2])
Postmenopausal state
Item
postmenopausal or recently postmenopausal
boolean
C0232970 (UMLS CUI [1])
Operative Surgical Procedures Breast Carcinoma
Item
recent surgery for breast cancer
boolean
C0543467 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0678222 (UMLS CUI [1,2])
Hormone Receptor Status Estrogen receptor positive | Hormone Receptor Status progesterone receptor positive
Item
estrogen receptor positive and/or progesterone receptor positive hormone receptor status
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0279754 (UMLS CUI [1,3])
C0019929 (UMLS CUI [2,1])
C0449438 (UMLS CUI [2,2])
C0279759 (UMLS CUI [2,3])
C0449438 (UMLS CUI [1,2])
C0279754 (UMLS CUI [1,3])
C0019929 (UMLS CUI [2,1])
C0449438 (UMLS CUI [2,2])
C0279759 (UMLS CUI [2,3])
letrozole
Item
no prior treatment with letrozole
boolean
C0246421 (UMLS CUI [1])
ID.6
Item
other protocol-defined inclusion criteria may apply.
boolean
Metastatic Neoplasm
Item
metastatic disease
boolean
C2939420 (UMLS CUI [1])
Bilateral Disease Invasive
Item
invasive bilateral disease
boolean
C1511113 (UMLS CUI [1,1])
C0205281 (UMLS CUI [1,2])
C0205281 (UMLS CUI [1,2])
Spinal Fracture | Hip Fracture
Item
clinical or radiological evidence of existing fracture in spine or hip
boolean
C0080179 (UMLS CUI [1])
C0019557 (UMLS CUI [2])
C0019557 (UMLS CUI [2])
Intravenous bisphosphonates
Item
prior treatment with iv bisphosphonates in the past 12 months
boolean
C1955566 (UMLS CUI [1])
Diphosphonates Oral Discontinued
Item
current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)
boolean
C0012544 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1444662 (UMLS CUI [1,3])
C1527415 (UMLS CUI [1,2])
C1444662 (UMLS CUI [1,3])
tibolone Use
Item
use of tibolone within 6 months
boolean
C0076660 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,2])
Parathyroid Hormone Use
Item
prior use of parathyroid hormone for more than 1 week
boolean
C0030520 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,2])
Malignant Neoplasms
Item
previous or concomitant malignancy
boolean
C0006826 (UMLS CUI [1])
Abnormal renal function
Item
abnormal renal function
boolean
C0151746 (UMLS CUI [1])
Disease Effect bone metabolism
Item
history of disease effecting bone metabolism
boolean
C0012634 (UMLS CUI [1,1])
C1280500 (UMLS CUI [1,2])
C0596204 (UMLS CUI [1,3])
C1280500 (UMLS CUI [1,2])
C0596204 (UMLS CUI [1,3])
ID.17
Item
other protocol-defined exclusion criteria may apply.
boolean